Relmada Therapeutics (RLMD) 10-K 24 Mar 21 2020 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Mar. 15, 2021	Jun. 30, 2020
Document Information Line Items
Entity Registrant Name	RELMADA THERAPEUTICS, INC.
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		16,745,930
Entity Public Float			$ 694,982,670
Amendment Flag	false
Entity Central Index Key	0001553643
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity File Number	000-55347
Entity Incorporation, State or Country Code	NV
Entity Interactive Data Current	Yes

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2019
Current assets:
Cash and cash equivalents	$ 2,495,397	$ 36,278,519	$ 9,216,554
Short-term investments	114,595,525	80,164,823
Other receivable			176,980
Lease payments receivable – short term	79,457	73,091	70,102
Prepaid expenses	903,190	423,863	520,745
Total current assets	118,073,569	116,940,296	9,984,381
Fixed assets, net of accumulated depreciation	1,258	5,010	7,210
Other assets	25,000	25,000	25,000
Lease payments receivable – long term	86,377	165,834	203,142
Total assets	118,186,204	117,136,140	10,219,733
Current liabilities:
Accounts payable	8,346,475	522,663	924,359
Accrued expenses	4,256,983	824,936	1,317,855
Notes payable		110,247	364,204
Total current liabilities	12,603,458	1,457,846	2,606,418
Total liabilities	12,603,458	1,457,846	2,606,418
Stockholders’ Equity:
Preferred stock
Common stock, $0.001 par value, 50,000,000 shares authorized, 16,332,939, 14,457,013 and 9,744,643 shares issued and outstanding, respectively	16,333	14,457	9,744
Additional paid-in capital	284,881,716	235,522,746	119,265,938
Accumulated deficit	(179,315,303)	(119,858,909)	(111,662,367)
Total stockholders’ equity	105,582,746	115,678,294	7,613,315
Total liabilities and stockholders’ equity	118,186,204	117,136,140	10,219,733
Class A Convertible Preferred Stock
Stockholders’ Equity:
Preferred stock

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2019
Preferred stock par value (in Dollars per share)	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	200,000,000	200,000,000	200,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000	50,000,000
Common stock, shares issued	16,332,939	14,457,013	9,744,643
Common stock, shares outstanding	16,332,939	14,457,013	9,744,643
Class A Convertible Preferred Stock
Preferred stock par value (in Dollars per share)	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	3,500,000	3,500,000	3,500,000
Preferred stock, shares issued
Preferred stock, shares outstanding

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2019
Operating expenses:
Research and development	$ 3,513,606	$ 35,972,731	$ 7,859,453	$ 7,024,747
General and administrative	4,757,999	24,865,942	7,249,858	5,703,173
Total operating expenses	8,271,605	60,838,673	15,109,311	12,727,920
Loss from operations	(8,271,605)	(60,838,673)	(15,109,311)	(12,727,920)
Other income (expenses):
Change in fair value of derivative liabilities				(54,634)
Interest income (expense), net	75,063	1,399,225	104,112	(761,038)
Realized loss on short-term investments		(156,213)
Unrealized gain on short-term investments		139,267
Loss on extinguishment of debt				(3,774,468)
Total other income (expenses), net	75,063	1,382,279	104,112	(4,590,140)
Net loss	$ (8,196,542)	$ (59,456,394)	$ (15,005,199)	$ (17,318,060)
Net loss per common share – basic and diluted (in Dollars per share)	$ (0.77)	$ (3.81)	$ (1.62)	$ (2.74)
Weighted average number of common shares outstanding – basic and diluted (in Shares)	10,577,866	15,594,228	9,241,219	6,311,769

Consolidated Statements of Stoc

Consolidated Statements of Stockholders’ Equity (Deficit) - USD ($)	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Jun. 30, 2018	$ 3,137	$ 88,828,094	$ (94,344,307)	$ (5,513,076)
Balance (in Shares) at Jun. 30, 2018	3,137,468
Cumulative effect of Write-off of Derivative Liabilities under ASU 2017-11		59,397		59,397
Adjusted Balance	$ 3,137	88,887,491	(94,344,307)	(5,453,679)
Adjusted Balance (in Shares)	3,137,468
Stock-based compensation expense		1,213,996		1,213,996
Conversion of notes and accrued interest	$ 2,683	11,802,150		11,804,833
Conversion of notes and accrued interest (in Shares)	2,682,917
Equity units issued for cash, net	$ 3,975	17,756,660		17,760,635
Equity units issued for cash, net (in Shares)	3,975,115
Shares relinquished by former officer	$ (76)	(394,334)		(394,410)
Shares relinquished by former officer (in Shares)	(75,848)
Issuance of common stock for cashless exercises of warrants from consultants and Series A Preferred Stock warrant holder	$ 25	(25)
Issuance of common stock for cashless exercises of warrants from consultants and Series A Preferred Stock warrant holder (in Shares)	24,991
Net loss			(17,318,060)	(17,318,060)
Balance at Jun. 30, 2019	$ 9,744	119,265,938	(111,662,367)	7,613,315
Balance (in Shares) at Jun. 30, 2019	9,744,643
Stock-based compensation expense		2,367,001		2,367,001
Equity units issued for cash, net	$ 3,951	109,443,531		109,447,482
Equity units issued for cash, net (in Shares)	3,951,299
Warrants exercised	$ 657	4,446,381		4,447,038
Warrants exercised (in Shares)	656,943
Cashless exercise of warrants	$ 43	(43)
Cashless exercise of warrants (in Shares)	42,644
Cashless exercise of options	$ 62	(62)
Cashless exercise of options (in Shares)	61,484
Net loss			(8,196,542)	(8,196,542)
Balance at Dec. 31, 2019	$ 14,457	235,522,746	(119,858,909)	115,678,294
Balance (in Shares) at Dec. 31, 2019	14,457,013
Stock-based compensation expense		20,777,272		20,777,272
Equity offering, net	$ 428	19,791,216		$ 19,791,644
Equity offering, net (in Shares)	427,700
Equity units issued for cash, net (in Shares)				19,791,644
Warrants exercised	$ 1,160	8,055,256		$ 8,056,416
Warrants exercised (in Shares)	1,159,989
Cashless exercise of warrants	$ 42	(42)
Cashless exercise of warrants (in Shares)	42,475
Options exercised	$ 156	735,358		735,514
Options exercised (in Shares)	155,558
Cashless exercise of options	$ 90	(90)
Cashless exercise of options (in Shares)	90,204
Net loss			(59,456,394)	(59,456,394)
Balance at Dec. 31, 2020	$ 16,333	$ 284,881,716	$ (179,315,303)	$ 105,582,746
Balance (in Shares) at Dec. 31, 2020	16,332,939

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2019
Cash flows from operating activities
Net loss	$ (8,196,542)	$ (59,456,394)	$ (15,005,199)	$ (17,318,060)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	2,200	3,752	4,363	4,870
Stock-based compensation	2,367,001	20,777,272	3,165,153	1,213,996
Realized loss on short-term investments		156,213
Unrealized gain on short-term investments		(139,267)
Amortization of deferred financing costs				661,168
Change in fair value of derivative liabilities				54,634
Fair value of shares relinquished			(394,410)	(394,410)
Loss on promissory note extinguishment				3,774,468
Changes in operating assets and liabilities:
Prepaid expenses and other assets	96,882	(479,327)	471,912	270,167
Other receivable	176,980			(169,363)
Lease payment receivable	34,319	73,091	67,235	64,486
Accounts payable	(401,696)	7,823,812	163,773	158,920
Accrued expenses	(492,919)	3,432,047	(565,611)	1,181,270
Net cash used in operating activities	(6,413,775)	(27,808,801)	(12,092,784)	(10,497,854)
Cash flows from investing activities
Purchase of investments	(84,849,198)	(182,051,630)	(84,849,198)
Sale of investments	4,684,375	147,603,982	4,684,375
Net cash used in investing activities	(80,164,823)	(34,447,648)	(80,164,823)
Cash flows from financing activities
Proceeds from issuance of common stock, net of fees	109,447,482	19,791,644	122,031,032	17,760,635
Proceeds from warrants exercised for common stock	4,447,038	8,056,416	4,447,038
Proceeds from options exercised for common stock		735,514
Principal payment of notes payable	(253,957)	(110,247)	(368,695)	(285,170)
Net cash provided by financing activities	113,640,563	28,473,327	126,109,375	17,475,465
Net increase/(decrease) in cash and cash equivalents	27,061,965	(33,783,122)	33,851,768	6,977,611
Cash and cash equivalents at beginning of the period	9,216,554	36,278,519	2,426,751	2,238,943
Cash and cash equivalents at end of the period	36,278,519	2,495,397	36,278,519	9,216,554
Cash paid during the period for:
Income taxes
Interest	4,610	2,415	9,034	5,933
Non-cash investing and financing transactions:
Notes payable issued in connection with director and officer insurance policies			364,204	364,204
Cashless exercise of warrants for common stock	43	42	68	25
Cashless exercise of options for common stock	62	90	$ 62
Write off for derivative liability due to adoption of ASU 2017-11				59,397
Conversion of promissory notes and accrued interest to common stock				$ 8,030,365

Business

Business	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
BUSINESS	NOTE 1 - BUSINESS Relmada Therapeutics Inc. (Relmada, the Company) (a Nevada corporation) is a clinical-stage, publicly traded biotechnology company focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. esmethadone is a New Chemical Entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. On October 7, 2019, our application to list our common stock on the NASDAQ Capital Market was approved. On October 10, 2019, our common stock began trading on Nasdaq under our existing symbol, “RLMD.” On December 19, 2019, the Board of Directors of the Company approved a change to its end of fiscal year from June 30 to December 31. The change in fiscal year was effective for the Company’s 2020 fiscal year. In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s research and development will be successfully completed or that any product will be approved or commercially viable. The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with the Food and Drug Administration (FDA) and other governmental regulations and approval requirements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). The consolidated financial statements include the Company’s accounts and those of the Company’s wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation. On September 26, 2019, the Company’s Board of Directors approved a 1-to-4 reverse split of the Common Stock, which was effective on the NASDAQ Capital Market on September 30, 2019. As a result of the reverse stock split, every 4 shares of issued and outstanding common stock were converted into 1 share of issued and outstanding common stock, with all fractional shares rounded up to the nearest whole share, and the Company’s authorized share of common stock were reduced from 200,000,000 to 50,000,000 shares. All share and per share amounts have been retroactively restated to reflect this reverse stock split. Change in Fiscal Year The Company changed its fiscal year end to December 31 from June 30. The information for the year ended December 31, 2019 is presented for comparative purposes only and is unaudited. Liquidity As shown in the accompanying financial statements, the Company incurred negative operating cash flows of $27,808,801 for the year ended December 31, 2020 and has an accumulated deficit of $179,315,303 from inception through December 31, 2020. Relmada has funded its past operations through equity raises and most recently in the year ended December 31, 2020, Relmada raised net proceeds from the sale of common stock of $19,791,644, $8,056,416 through the exercise of warrants and $735,514 through the exercise of options. Management believes that due to the recent equity raises completed and exercises of outstanding warrants and the current cash position on its balance sheet, it has obtained sufficient funding to continue ongoing operations for at least 12 months from the issuance of this annual report. Since December 31, 2020 and to date, the Company has received approximately $1,909,200 in warrant and option exercises, which resulted in the Company having approximately $105.3 million in cash, cash equivalents, and short term investments at March 15, 2021. Based on its budgeted cash flow requirements, the Company believes these funds are sufficient to fund its ongoing operations for at least 12 months after the issuance of these consolidated financial statements. Regardless of the results of any ongoing clinical trial, the Company has control over its expenditures and has the ability to adjust spending accordingly based on the budgeted cash flow requirements developed and the excess cash on hand. Management believes that their existing cash and cash equivalents will enable them to fund operating expenses and capital expenditure requirements for at least the next 12 months from the issuance of these consolidated financial statements. Beyond that point management will evaluate the size and scope of any subsequent trials that will affect the timing of additional financings through public or private sales of equity or debt securities or from bank or other loans or through strategic collaboration and/or licensing agreements. Any such expenditures related to any subsequent trials will not be incurred until such additional financing is raised. Further, additional financing related to subsequent trials does not affect the Company’s conclusion that based on the cash on hand and the budgeted cash flow requirements, the Company has sufficient funds to maintain operations for at least 12 months from the issuance of these consolidated financial statements. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates. The significant estimates are stock-based compensation expenses, the valuation of derivative liabilities and recorded amounts related to income taxes. Cash and Cash Equivalents The Company considers cash deposits and all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company’s cash deposits are held at two high-credit-quality financial institutions. The Company’s cash deposits of $2,495,397 at December 31, 2020 at these institutions exceed federally insured limits. Short-term Investments The Company’s investments consist entirely of mutual funds. The securities are measured at fair value based on the net asset value (“NAV”). The Company has adopted FASB ASU 2016-01, Financial Instruments, for the year ended December 31, 2020 which requires substantially all equity investments in nonconsolidated entities to be measured at fair value with recurring changes recognized in earnings, except for those accounted for using equity method accounting. Changes in fair value of the securities are recorded as part of other income on the consolidated statement of operations. Short term investment activity is presented in the investing activities section on the consolidated statement of cash flows. Short-term investments at December 31, 2020 consisted of mutual funds with a fair value of $114,595,525. Patents Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain. Fixed Assets Fixed assets are stated at cost less accumulated depreciation. Fixed assets are comprised of computers and software. Depreciation is calculated using the straight-line method over the estimated useful life of the assets. Computers and software have an estimated useful life of three years. Furniture and fixtures have an estimated useful life of approximately seven years. Leases The Company recognizes their leases with a term of greater than a year on the balance sheet by recording right-of-use assets and lease liabilities. Leases can be classified as either operating leases or finance leases. Operating leases will result in straight-line lease expense, while finance leases will result in front-loaded expense. The Company’s lease consists of an operating leases for office space. The Company does not recognize a lease liability or right-of-use asset on the balance sheet for short-term leases. Instead, the Company recognizes short-term lease payments as an expense on a straight-line basis over the lease term. A short-term lease is defined as a lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. Fair Value of Financial Instruments The Company’s financial instruments primarily include cash, short term investments derivative liabilities and accounts payable. Due to the short-term nature of cash and accounts payable the carrying amounts of these assets and liabilities approximate their fair value. Derivatives are recorded at fair value at each period end. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows: Level 1 Inputs - Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 Inputs - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means. Level 3 Inputs - Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity). The Company’s short-term investment instruments of $114,595,525 at December 31, 2020 are classified using Level 1 inputs within the fair value hierarchy because they are valued using NAV. Unrealized gains and losses are recorded in the consolidated statement of operations as unrealized gain on short-term investments. The Company recorded an unrealized gain of $139,267, included in other income for the period ended December 31, 2020. Fair Value on a Recurring Basis As required by Accounting Standard Codification (ASC) Topic No. 820 - 10 Fair Value Measurement Income Taxes The Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in the tax rate is recognized in income or expense in the period that the change is effective. Tax benefits are recognized when it is probable that the deduction will be sustained. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will either expire before the Company is able to realize the benefit, or that future deductibility is uncertain. At December 31, 2020 and 2019 and June 30, 2019, the Company had recorded a valuation allowance to the full extent of the Company’s net deferred tax assets since the likelihood of realization of the benefit does not meet the more likely than not threshold. The Company files a U.S. Federal income tax return and various state returns. Uncertain tax positions taken on our tax returns will be accounted for as liabilities for unrecognized tax benefits. The Company will recognize interest and penalties, if any, related to unrecognized tax benefits in general and administrative expenses in the statements of operations. There were no liabilities recorded for uncertain tax positions at December 31, 2020 and 2019, and June 30, 2019. The open tax years, subject to potential examination by the applicable taxing authority, for the Company are from June 30, 2018 forward. Research and Development Research and development costs primarily consist of research contracts for the advancement of product development, salaries and benefits, stock-based compensation, and consultants. The Company expenses all research and development costs in the period incurred. The Company makes an estimate of costs in relation to clinical study contracts. The Company analyzes the progress of studies, including the progress of clinical studies and phases, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Stock-Based Compensation The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period during which an employee is required to provide service in exchange for the award - the requisite service period. The grant-date fair value of employee share options is estimated using the Black-Scholes option pricing model adjusted for the unique characteristics of those instruments. Net Loss per Common Share Basic net loss per common share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per common share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of Class A convertible preferred stock, Series A preferred stock, restricted stock awards, options and warrants to purchase common stock. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net losses in each period. The potentially dilutive securities that would be anti-dilutive due to the Company’s net loss are not included in the calculation of diluted net loss per share attributable to common stockholders. The anti-dilutive securities are as follows (in common stock equivalent shares): Year ended (Unaudited) Year ended Six Months Year ended 2020 2019 2019 2019 Common stock warrants 2,670,633 3,646,872 3,646,872 4,429,982 Common stock options 3,905,737 3,615,602 3,615,602 1,473,314 Total 6,576,370 7,262,474 7,262,474 5,903,296 Recent Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, “ Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes In August 2018, FASB issued ASU 2018-13, Fair Value Measurement – Disclosure Framework (Topic 820). In November 2018, FASB issued ASU 2018-18 – Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606

Prepaid Expenses

Prepaid Expenses	12 Months Ended
	Dec. 31, 2020
Prepaid Expenses [Abstract]
PREPAID EXPENSES	NOTE 3 - PREPAID EXPENSES Prepaid expenses consisted of the following (rounded to nearest $00): December 31, December 31, June 30, Insurance $ 527,600 $ 223,600 $ 451,500 Research and Development 291,800 139,200 - Legal 11,000 11,000 7,500 Other 72,800 50,100 61,800 Total $ 903,200 $ 423,900 $ 520,800

Fixed Assets

Fixed Assets	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
FIXED ASSETS	NOTE 4 - FIXED ASSETS Fixed assets consisted of the following (rounded to nearest $00): Useful lives December 31, December 31, June 30, Computer and software 3 years $ 16,700 $ 16,700 $ 16,700 Less: accumulated depreciation (15,400 ) (11,700 ) (9,500 ) Fixed assets, net $ 1,300 $ 5,000 $ 7,200

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2020
Payables and Accruals [Abstract]
ACCRUED EXPENSES	NOTE 5 - ACCRUED EXPENSES Accrued expenses consisted of the following (rounded to nearest $00): December 31, December 31, June 30, Research and development $ 2,183,800 $ 134,500 $ 563,400 Professional fees 150,900 172,900 98,400 Accrued bonus 1,444,900 50,000 - Accrued vacation 351,200 124,600 96,700 Legal Settlement - 250,000 500,000 Other 126,200 92,900 59,400 Total $ 4,257,000 $ 824,900 $ 1,317,900

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 6 - NOTES PAYABLE In June 2019, the Company entered into a note for approximately $364,200 in conjunction with a renewal of its director and officer insurance policy. The interest rate was 3.09% per annum. The note matured on April 9, 2020. In June 2018, the Company entered into a note for approximately $285,200 in conjunction with a renewal of its director and officer insurance policy. The interest rate was 2.35% per annum. The note matured on April 9, 2019 and was repaid. At December 31, 2020 and 2019 and June 30, 2019, the note payable outstanding balances were approximately $0, $110,200, and $364,200, respectively.

Derivative Liabilities

Derivative Liabilities	12 Months Ended
	Dec. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE LIABILITIES	NOTE 7 - DERIVATIVE LIABILITIES ASC Topic No. 815 – “ Derivatives and Hedging” Until October 18, 2018, the Company had promissory notes with a redemption feature that was not clearly and closely related to the host instrument and therefore was considered an embedded derivative which was bifurcated and recorded as a derivative liability. In determining the fair value of the derivative liabilities, the Company used the Monte-Carlo pricing model. The assumptions used in the valuation model considers the probability of redemption, the length of time to maturity and value of the redemption feature. On October 12 and 18, 2018, the Company conducted closings on its private placement of securities. As a result of these closings, the outstanding promissory notes converted into common stock. The redemption feature associated with the promissory notes was valued on October 18, 2018 using the Black-Scholes model. The change in value of the derivative between July 1, 2018 and the October 18, 2018 was recorded as income. The notes were converted to common stock on October 18, 2018. The Company had no financial liabilities accounted for at fair value on a recurring basis as of December 31, 2020 and 2019 and June 30, 2019. The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as level 3 in the fair value hierarchy: Year ended Six months ended Year ended (Unaudited) December 31, December 31, December 31, June 30, 2020 2019 2019 2019 Beginning balance $ - $ - $ - $ 4,194,634 Adoption of ASU 2017-11 – warrants - - - (59,397 ) Fair value of derivative liabilities for redemption feature of promissory notes payable - - - - Change in fair value of derivative liabilities - - - 54,634 Extinguishment of derivative liabilities on conversion of promissory notes. - - - (4,189,871 ) Ending balance $ - $ - $ - $ - The Company had no financial liabilities classified as level 3 during the year ended December 31, 2020 and the six months ended December 31, 2019.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2020
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' EQUITY	NOTE 8 - STOCKHOLDERS’ EQUITY Common Stock During the year ended December 31, 2020 and the six months ended December 31, 2019 and year ended June 30, 2019, the Company issued 42,475, 42,644, and 24,991 shares of common stock for cashless exercise of 60,513, 88,751, and 25,004 warrants, respectively. During the year ended December 31, 2020 and the six months ended December 31, 2019 and year ended June 30, 2019, the Company issued 1,159,989, 656,943, and nil shares of common stock for the exercise of warrants for proceeds of $8,056,416, $4,447,038 and $nil, respectively. During the year ended December 31, 2020, the Company issued 90,204 shares of common stock for cashless exercise of 98,370 options. During the year ended December 31, 2020, the Company issued 155,558 shares of common stock for the exercise of options for proceeds of $735,514. During the six months ended December 31, 2019, the Company issued 61,484 shares of common stock for cashless exercise of 67,578 options. On May 15, 2020, the Company entered into an Open Market Sale Agreement with Jefferies LLC, as sales agent (“Jefferies”), pursuant to which the Company may offer and sell, from time to time, through Jefferies, shares of the Company’s common stock, having an aggregate offering price of up to $75,000,000. The Company is not obligated to sell any shares under the agreement. During the year ended December 31, 2020 the Company issued shares of common stock for net cash proceeds of $19,791,644 under the agreement. During the six months ended December 31, 2019, the Company closed on a private placement of 3,833,334 shares of common stock. The price per share was $30.00 to the public (with a price to the underwriters of $28.00 per share). The net proceeds from the closing was $108,621,733. Approximately, $478,000 of legal and professional fees were incurred in relation to the closing. The Company also closed on a private placement of 117,965 shares for $7.00 per share and net proceeds of $825,749 during the 3 rd During the year ended June 30, 2019, the Company closed on private placements of securities pursuant to Unit Purchase Agreements and Subscription Agreements, each dated as shown below. The price per unit (comprising one common stock and a 5 year warrant to purchase 2.60 or 2.00 of a share of common stock) was $3.60, $5.60 or $6.00. The Company issued an aggregate of 3,975,115 shares of common stock to investors in these closings, for net proceeds of $17,839,656. Approximately $79,000 of legal costs were incurred that were not allocated to the individual closings. Date of closing Common Stock Issued Warrants issued Unit Price Net proceeds Warrant exercise price Warrant coverage October 12, 2018 501,027 325,668 $ 3.60 $ 1,630,991 $ 6.00 .65 October 18, 2018 410,084 266,555 $ 3.60 $ 1,287,007 $ 6.00 .65 November 2, 2018 374,864 243,662 $ 3.60 $ 1,215,242 $ 6.00 .65 December 5, 2018 334,694 217,550 $ 3.60 $ 1,083,307 $ 6.00 .65 February 12, 2019 201,389 130,903 $ 3.60 $ 725,000 $ 6.00 .65 March 27, 2019 178,572 89,286 $ 5.60 $ 1,000,000 $ 9.00 .50 May 14, 2019 569,083 284,541 $ 6.00 $ 3,168,865 $ 9.00 .50 June 14, 2019 612,914 306,456 $ 6.00 $ 3,274,331 $ 9.00 .50 June 20, 2019 720,799 360,399 $ 6.00 $ 4,059,050 $ 9.00 .50 June 28, 2019 71,689 35,845 $ 6.00 $ 395,863 $ 9.00 .50 Total 3,975,115 2,260,865 $ 17,839,656 Approximately $177,000 of the June 28 financing was in Other Receivable at June 30, 2019 and was received in July, 2019. The October 12, 2018 and October 18, 2018 financings represented an Equity Financing as defined in the Convertible Promissory Note agreement. As a result of the October 12, 2018 and October 18, 2018 financings, the Company’s outstanding 7% Convertible Promissory Notes and accumulated interest converted into 2,682,917 shares of common stock. During the year ended December 31, 2020, the six months ended December 31, 2019, and years ended June 30, 2019, there were no common stock shares issued for issuances of restricted common stocks, respectively. Placement Agent Warrants During the year ended June 30, 2019, the Company issued an aggregate of 357,396 warrants to the placement agent in connection with the closings. The agent warrants have an exercise price between $3.96 and $9.00, are non-cancellable, vest upon issuance and expire on the fifth anniversary of the warrant date of issuance. Warrants have a five year term and an aggregate fair value of approximately $1,809,535 calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rates between 1.74-3.09% (2) expected life of 5 years, (3) expected volatility between 100.7-103.4%, and (4) zero expected dividends. Stock-based compensation - options In December 2014, the Board of Directors adopted and the shareholders approved Relmada’s 2014 Stock Option and Equity Incentive Plan, as amended (the “Plan”), which allows for the granting of common stock awards, stock appreciation rights, and incentive and nonqualified stock options to purchase shares of the Company’s common stock to designated employees, non-employee directors, and consultants and advisors. The Plan allowed for the granting of 5,152,942 options or stock awards. Stock options are exercisable generally for a period of 10 years from the date of grant and generally vest over four years. As of December 31, 2020, 1,247,205 shares were available for future grants under the Plan. The Company uses the simplified method for share-based compensation to estimate the expected term for employee option awards for share-based compensation in its option-pricing model. During the year ended December 31, 2020, the Company awarded a total of 1,000,000 options to employees with exercise prices ranging from $28.00- $45.61 and a 10-year term vesting over 4-year period. The options have an aggregate fair value of $32.4 million calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 0.36%-0.83% (2) expected life of 6.25 years, (3) expected volatility of 101%-108%, and (4) zero expected dividends. During the year ended December 31, 2020, the Company recognized additional compensation expense of approximately $1,500,000 related to acceleration of vesting and a nominal amount related to the modification of certain options in connection with the separation and settlement agreement with Dr. Ottavio Vitolo (see note 11). During the year ended December 31, 2020, the Company recognized compensation expense of approximately $484,000 related to the extended period of time to allow for some options to vest under the separation and settlement agreement with Dr. Thomas Wessel. This was considered a Type III modification and as a result the total expense of $1.8 million previously recognized was reversed as the options would not have vested prior to the modification (see note 11). On December 19, 2019, the Company granted employees options to purchase a total of 1,295,000 shares of common stock. The options have a ten-year term and have an exercise price of $43.47 and vest over 4 years. The options have an aggregate fair value of $46,904,043 calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 1.79% (2) expected life of 6.25 years, (3) expected volatility of 108.2%, and (4) zero expected dividends. On December 19, 2019, the Company granted a consultant options to purchase a total of 10,000 shares of common stock. The options have a ten-year term and have an exercise price of $43.47 and vest immediately. The options have an aggregate fair value of $338,992 calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 1.73% (2) expected life of 5 years, (3) expected volatility of 107.4%, and (4) zero expected dividends. On April 1, 2019, the Company granted various employees options to purchase a total of 37,500 shares of common stock. The options have a ten-year term and have an exercise price of $7.04 and vest over 4 years. The options have an aggregate fair value of $214,000 calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 2.37% (2) expected life of 6.25 years, (3) expected volatility of 101.5%, and (4) zero expected dividends. On December 20, 2018, the Company granted various employees options to purchase a total of 675,000 shares of common stock. The options have a ten-year term and have an exercise price of $4.60 and vest over 4 years. The options have an aggregate fair value of $2,500,000 calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 2.69% (2) expected life of 6.25 years, (3) expected volatility of 102.3%, and (4) zero expected dividends. A summary of the changes in options outstanding for the periods ended December 31, 2020 and 2019, and June 30, 2019 is as follows: Number of Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term Aggregate Intrinsic Outstanding and expected to vest at June 30, 2018 767,220 $ 5.80 8.8 $ 511,000 Granted 712,500 4.73 9.5 - Forfeited (6,406 ) - - - Outstanding and expected to vest at June 30, 2019 1,473,314 $ 5.18 8.6 $ 4,668,153 Granted 2,205,000 29.32 9.8 - Exercised (62,712 ) - - $ - Outstanding and expected to vest at December 31, 2019 3,615,602 $ 19.96 9.2 $ 74,837,043 Granted 1,000,000 39.50 9.3 - Exercised (253,927 ) - - - Forfeited (455,938 ) - - - Outstanding and expected to vest at December 31, 2020 3,905,737 $ 24.32 8.4 $ 48,952,339 Options exercisable at December 31, 2020 1,241,359 $ 16.73 7.7 $ 22,960,117 At December 31, 2020, the Company has unrecognized stock-based compensation expense of approximately $53,502,000 related to unvested stock options over the weighted average remaining service period of 3.04 years. The weighted average fair value of options granted during the years ended December 31, 2020 and 2019, the six months ended December 31, 2019 and the year ended June 30, 2019 was approximately $32.45, $24.00 (unaudited), $24.31 and $3.84 per share, respectively, on the date of grant using the Black-Scholes option pricing model with the following assumptions: (Unaudited) Years Ended Years Ended Six Months ended Year ended December 31, December 31, December 31, June 30, 2020 2019 2019 2019 Risk free interest rate 0.36 to 0.83 % 1.73 to 2.37 % 1.73 to 1.79 % 2.37 to 2.69 % Dividend yield 0 % 0 % 0 % 0 % Volatility 101-108 % 101.5-108 % 107.4-108.2 % 101.5-102.3 % Expected term (in years) 6.25 5 to 6.25 5 to 6.25 6.25 Warrants A summary of the changes in outstanding warrants during the year ended December 31, 2020 and six months ended December 31. 2019, and year ended June 30, 2019 is as follows: Number of Shares Weighted Average Exercise Price Per Share Outstanding at June 30, 2018 2,453,757 $ 15.845 Issued 2,691,123 $ 7.10 Exercised (25,004 ) $ 0.004 Forfeited/Expired (689,894 ) $ 18.94 Outstanding at June 30, 2019 4,429,982 $ 7.12 Issued 21,250 $ 10.25 Exercised (740,694 ) $ 7.80 Forfeited/Expired (63,666 ) $ 13.89 Outstanding at December 31, 2019 3,646,872 $ 6.83 Issued 250,000 $ 33.32 Exercised (1,211,199 ) $ 7.27 Forfeited/Expired (15,040 ) $ 16.80 Outstanding at December 31, 2020 2,670,633 $ 9.11 Warrants exercisable at December 31, 2020 2,646,257 $ 9.16 Included in the warrants outstanding at June 30, 2018 are 643,643 warrants that expired in the year ended June 30, 2019. These warrants had an exercise price that was subject to downward adjustment on the sale of equity at prices below their original exercise price. On December 16, 2020, the Company granted 20,000 warrants to a consultant with an exercise price of $34.87, a 5-year term and vesting over 4 years. The warrants have an aggregated fair value of $479 thousand using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 0.37% (2) expected life of 3.75 years, (3) expected volatility of 105%, and (4) zero expected dividends On December 16, 2020, the Company granted 108,000 warrants to consultants with an exercise price of $34.87, a 5-year term and vesting based on future events. The warrants have an aggregated fair value of $2.86 million that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 0.37% (2) expected life of 5 years, (3) expected volatility of 105%, and (4) zero expected dividends On April 27, 2020, the Company granted 2,000 warrants to a consultant with an exercise price of $37.67, a 5-year term and immediate vesting. The warrants have an aggregated fair value of $48 thousand that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 0.27% (2) expected life of 2.5 years, (3) expected volatility of 116%, and (4) zero expected dividends. On April 1, 2020, the Company granted 120,000 warrants to consultants with an exercise price of $31.59, a 5-year term and immediate vesting. The warrants have an aggregated fair value of $2.5 million that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 0.26% (2) expected life of 2.5 years, (3) expected volatility of 118%, and (4) zero expected dividends. On October 8, 2019, the Company granted 15,000 warrants to a contractor with an exercise price of $10.85, non-cancellable term and immediate vesting. The warrants have an aggregated fair value of $121,252 that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 1.36% (2) expected life of 5 years, (3) expected volatility of 100%, and (4) zero expected dividends. On August 1, 2019, the Company granted 6,250 warrants to a contractor with an exercise price of $8.80, a 10-year term and immediate vesting. The warrants have an aggregated fair value of $41,386 that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 1.68% (2) expected life of 5 years, (3) expected volatility of 101.1%, and (4) zero expected dividends. On March 9, 2019, the Company granted 17,857 warrants to a consultant with an exercise price of $7.00, a 5-year term and immediate vesting. The warrants have an aggregated fair value of $95,131 that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 2.42% (2) expected life of 5 years, (3) expected volatility of 102.0%, and (4) zero expected dividends. On January 1, 2019, the Company granted 30,000 warrants to a contractor with an exercise price of $4.60, a 10-year term and quarterly vesting over four years vesting. The warrants have an aggregated fair value of $112,183 that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 2.49% (2) expected life of 6.25 years, (3) expected volatility of 102.0%, and (4) zero expected dividends. On December 20, 2018, the Company granted 25,000 warrants to a contractor with an exercise price of $4.60, a 10-year term and immediate vesting. The warrants have an aggregated fair value of $93,762 that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 2.69% (2) expected life of 6.25 years, (3) expected volatility of 102.3%, and (4) zero expected dividends. During the year ended June 30, 2019, the Company issued an aggregate of 2,260,860 warrants to investors in connection with private placements, with a fair value of approximately $11,420,300. The exercise price ranges from $6.00 to $9.00, vested upon issuance, are non-cancellable and expire on the fifth anniversary from issuance. Variables used in the Black-Scholes option-pricing model include: (1) discount rates of 1.74-3.09% (2) expected life of 5 years, (3) expected volatility of 100.7-103.4%, and (4) zero expected dividends. At December 31, 2020, the Company had $3.4 million of unrecognized stock-based compensation expense related to outstanding warrants. At December 31, 2020, the aggregate intrinsic value of warrants vested and outstanding was $61.2 million. Stock-based compensation by class of expense The following summarizes the components of stock-based compensation expense which includes common stock, stock options, warrants and restricted stock in the consolidated statements of operations (rounded to nearest $00): (Unaudited) Year Year Six Months ended Year ended December 31, December 31, December 31, June 30, 2020 2019 2019 2019 Research and development $ 4,038,500 $ 360,900 $ 174,500 $ 215,900 General and administrative 16,738,800 2,804,300 2,192,500 998,100 Total $ 20,777,300 $ 3,165,200 $ 2,367,000 $ 1,214,000

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 9 - INCOME TAXES No provision or benefit for federal or state income taxes has been recorded because the Company has incurred net losses for all periods presented and has recorded a valuation allowance against its deferred tax assets. No provision or benefit for federal or state income taxes has been recorded because the Company has incurred net losses for all periods presented and has recorded a valuation allowance against its deferred tax assets. The components of the Company’s deferred tax assets are as follows at: December 31, December 31, June 30, Deferred tax assets: Federal net operating loss $ 15,227,000 $ 13,022,000 $ 13,555,000 State net operating loss 9,361,000 7,912,000 8,252,000 Research and development tax credits 3,407,000 1,499,000 1,230,000 Capitalized R&D 14,387,000 3,168,000 - Nonqualified Stock Options 7,352,000 172,000 - Accruals 645,000 133,000 206,000 Other 41,000 45,000 46,000 Less: valuation allowance (50,420,000 ) (25,951,000 ) (23,289,000 ) Total $ - $ - $ - On March 27, 2020, the Coronavirus Aid Relief and Economic Security (“CARES”) Act was signed into law. The Act contains several new or changed income tax provisions, including but not limited to the following: increased limitation threshold for determining deductible interest expense, class life changes to qualified improvements (in general, from 39 years to 15 years) and the ability to carry back net operating losses (“NOLs”) incurred from tax years 2018 through 2020 up to the five preceding tax years. Most of these provisions are either not applicable or have no material effect on the Company. The Company has maintained a full valuation allowance against its deferred tax assets at December 31, 2020 and 2019, and June 30, 2019. A valuation allowance is required to be recorded when it is more likely than not that some portion or all of the net deferred tax assets will not be realized. Since the Company cannot be assured of realizing the net deferred tax asset, a full valuation allowance has been provided. The valuation allowance increased/(decreased) for the year ended December 31, 2020, the six months December 31, 2019 and the year ended June 30, 2019, by approximately $24,469,000, $2,662,000, and $4,357,000, respectively. Deferred tax asset for net operating loss carryforwards at December 31, 2020 was adjusted with the corresponding offset to valuation allowance. At December 31, 2020, the Company had federal, New York State and New York City net operating loss (NOL) carryforwards of approximately $72,507,000, $68,854,000 and $68,470,000 respectively, which begin expiring in 2027, 2032 and 2032 respectively. Approximately $27,037,000 federal NOL can be carried forward indefinitely but it is limited to 80% of future taxable income. The Company also has federal research and development tax credit carryforwards of approximately $3,407,000 that will begin to expire in 2028. The Company's ability to use its NOL carryforwards may be limited if it experiences an "ownership change" as defined in Section 382 ("Section 382") of the Internal Revenue Code of 1986, as amended. An ownership change generally occurs if certain stockholders increase their aggregate percentage ownership of a corporation's stock by more than 50 percentage points over their lowest percentage ownership at any time during the testing period, which is generally the three-year period preceding any potential ownership change. The Company has not completed an analysis to determine whether any such limitations have been triggered as of December 31, 2020. A reconciliation of the statutory tax rate to the effective tax rate is as follows: Year Ended (Unaudited) Six Months Ended Year Ended Statutory federal income tax rate 21.00 % 21.00 % 21 % 21 % State (net of federal benefit) 15.50 % 16.21 % 11.96 % 9.5 % Non-deductible expenses 0.42 % (4.24 )% (5.75 )% (6.3 )% R&D Credit 3.21 % 3.02 % - % - % Other 1.01 % 1.08 % 5.27 % 1 % Change in valuation allowance (41.15 )% (37.07 )% (32.48 )% (25.2 )% Effective income tax rate 0 % 0 % 0 % 0 % The Company does not have any uncertain tax positions at December 31, 2020, December 31, 2019 and June 30, 2019 that would affect its effective tax rate. The Company does not anticipate a significant change in the amount of unrecognized tax benefits over the next twelve months. Because the Company is in a loss carryforward position, the Company is generally subject to US federal and state income tax examinations by tax authorities for all years for which a loss carryforward is available. If and when applicable, the Company will recognize interest and penalties as part of income tax expense.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 10 - COMMITMENTS AND CONTINGENCIES License Agreements Wonpung On August 20, 2007, the Company entered into a License Development and Commercialization Agreement with Wonpung Mulsan Co, a shareholder of the Company. Wonpung has exclusive territorial rights in countries it selects in Asia to market up to two drugs the Company is currently developing and a right of first refusal (ROFR) for up to an additional five drugs that the Company may develop in the future as defined in more detail in the license agreement. The Company received an upfront license fee of $1,500,000 and will earn royalties of up to 12% of net sales for up to two licensed products it is currently developing. The licensing terms for the ROFR products are subject to future negotiations and binding arbitration. The terms of each licensing agreement will expire on the earlier of any time from 15 years to 20 years after licensing or on the date of commercial availability of a generic product to such licensed product in the licensed territory. Third Party Licensor Based upon a prior acquisition, the Company assumed an obligation to pay a third party (Dr. Charles E. Inturrisi and Dr. Paolo Manfredi - see below): (A) royalty payments up to 2% on net sales of licensed products that are not sold by sublicensee and (B) on each and every sublicense earned royalty payment received by licensee from its sublicensee on sales of license product by sublicensee, the higher of (i) 20% of the royalties received by licensee; or (ii) up to 2% of net sales of sublicensee. The Company will also make milestone payments of up to $4 or $2 million, for the first commercial sale of product in the field that has a single active pharmaceutical ingredient, and for the first commercial sale of product in the field of product that has more than one active pharmaceutical ingredient, respectively. As of December 31, 2020, the Company has not generated any revenue related to this license agreement. Inturrisi / Manfredi In January 2018, we entered into an Intellectual Property Assignment Agreement (the Assignment Agreement) and License Agreement (the “License Agreement” and together with the Assignment Agreement, the Agreements) with Dr. Charles E. Inturrisi and Dr. Paolo Manfredi (collectively, the Licensor). Pursuant to the Agreements, Relmada assigned its existing rights, including patents and patent applications, to esmethadone in the context of psychiatric use (the Existing Invention) to Licensor. Licensor then granted Relmada under the License Agreement a perpetual, worldwide, and exclusive license to commercialize the Existing Invention and certain further inventions regarding esmethadone in the context of other indications such as those contemplated above. In consideration of the rights granted to Relmada under the License Agreement, Relmada paid the Licensor an upfront, non-refundable license fee of $180,000. Additionally, Relmada will pay Licensor $45,000 every three months until the earliest to occur of the following events: (i) the first commercial sale of a licensed product anywhere in the world, (ii) the expiration or invalidation of the last to expire or be invalidated of the patent rights anywhere in the world, or (iii) the termination of the License Agreement. Relmada will also pay Licensor tiered royalties with a maximum rate of 2%, decreasing to 1.75%, and 1.5% in certain circumstances, on net sales of licensed products covered under the License Agreement. Relmada will also pay Licensor tiered payments up to a maximum of 20%, and decreasing to 17.5%, and 15% in certain circumstances, of all consideration received by Relmada for sublicenses granted under the License Agreement. Leases and Subleases As of January 1, 2019, the Company changed its corporate headquarters to 880 Third Avenue, 12th Floor, New York, New York 10022 pursuant to a lease agreement with an initial monthly rent of $7,500. The lease period was for one year. The lease agreement expired on December 31, 2019 and was renewed for calendar years 2020 and 2021. As the Company’s leases consist of one lease for their corporate headquarters, which is for a period of 12 months or less. The Company has elected the practical expedient and recognizes rent expense evenly over the 12 months. The Company incurred rent expense of approximately $165,900, 93,900, $47,100, and $114,800 for the year ended December 31, 2020 and December 31, 2019 (unaudited), the six months ended December 31, 2019 and year ended June 30, 2019, respectively. In June 2015, the Company entered into an Agreement of Lease (the Lease) for office space located at 275 Madison Avenue, 7th Floor, New York, New York 10016, its former corporate headquarter, with a third party. On March 10, 2016 and effective as of January 1, 2016, the Company entered into an Office Space License Agreement (the License) with Actinium Pharmaceuticals, Inc. (Actinium), with whom the Company shared two common board members until June 6, 2017, for the office space. The term of the License was three years from the effective date, with an automatic renewal provision. The cost of the License was approximately $16,600 per month for Actinium, subject to customary escalations and adjustments. The Company recorded the license fees as other income in the consolidated statements of operations. On June 8, 2017, the Company entered into an Amended and Restated License Agreement with Actinium. Pursuant to the terms of the agreement, Actinium will continue to license the furniture, fixtures, equipment and tenant improvements located in the office (FFE) for a license fee of $7,529 per month until December 8, 2022. Actinium shall have at any time during the term of this agreement the right to purchase the FFE for $496,914, less any previously paid license fees. The license of FFE qualifies as a sales-type lease. On June 8, 2017 the Company derecognized the underlying assets of $493,452, recognized discounted lease payments receivable of $397,049 using the discount rate of 8.38% and recognized loss on sales-type lease of fixed assets of $96,403. As of December 31, 2020 and 2019, and June 30, 2019, the balance of unearned interest income was approximately $14,900, $32,100 and 43,000, respectively. The future minimum lease payments to be received under the lease for each year as of December 31, 2020 are as follows: 2021 $ 90,348 2022 90,348 Total $ 180,696 Legal From time to time, the Company may become involved in lawsuits and other legal proceedings that arise in the course of business. Litigation is subject to inherent uncertainties, and it is not possible to predict the outcome of litigation with total confidence. Except as disclosed below, the Company is currently not aware of any legal proceedings or potential claims against it whose outcome would be likely, individually or in the aggregate, to have a material adverse effect on the Company’s business, financial condition, operating results, or cash flows. Lawsuit Brought by Former Officer In 2014, Relmada dismissed with prejudice its lawsuit against Najib Babul, which had sought to compel Dr. Babul, Relmada’s former President, to account for questionable expenditures of Relmada funds made while Babul controlled the Company. Relmada’s decision to end its claims was informed by the fact that Babul came forward with plausible explanations for some of the expenditures, and the fact that, because Babul was a former officer and director of Relmada being sued for his conduct in office, the Company was required to advance his expenses of the litigation; hence, Relmada was paying all the lawyers and consultants on both sides of the dispute. Relmada also agreed to reinstate certain stock purchase warrants in Babul’s name, which had been cancelled during the pendency of the litigation, and offered Babul the right to exchange his shares in Relmada Therapeutics, Inc. (a Delaware corporation and subsidiary of the Company) for shares in the Company. Babul has brought a second lawsuit against Relmada. Ruling on Relmada’s Motion to Dismiss, the United States District Court for the Eastern District of Pennsylvania dismissed Babul’s claims for breach of contract and intentional infliction of emotional distress, and left intact his claims for defamation, and wrongful use of civil process. On February 6, 2019, the Company entered into a settlement agreement in which Babul relinquished his 303,392 shares in Relmada, signed a consulting contract and Relmada committed to a $500,000 initial payment and four subsequent payments of $250,000 on March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019. For accounting purposes, no fair value was attributed to the consulting agreement. The Company recorded a loss on settlement of $1,105,590 included in the general and administrative expenses for the year ended June 30, 2019. The loss represents the total cash payments of $1,500,000 less the fair value of the shares relinquished of $394,410. Lawsuit Brought by Current Employee On July 15, 2020, an employee of the Company filed a Complaint alleging unequal pay based on gender and other employment-based claims. The Company intends to defend the lawsuit vigorously, it is currently in discovery and the ultimate outcome is not known.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 11 - RELATED PARTY TRANSACTIONS Effective March 6, 2020, Dr. Vitolo entered into a Separation and Severance Agreement with the Company. Pursuant to the terms of the agreement, the Company agreed to pay Dr. Vitolo severance of $200,000 in accordance with his employment contract. In addition, Dr. Vitolo’s options granted under the Company’s 2014 Stock Option and Equity Incentive Plan continued to vest until September 6, 2020. Dr. Vitolo shall have until March 6, 2021 to exercise his vested options and he shall be allowed to use a cashless exercise provision to exercise his vested options. The agreement also contains customary confidentiality, release, and non-disparagement provisions, and the Company agreed to pay accrued and unpaid salary, vacation time and attorney’s fees totaling approximately $45,000. Effective December 31, 2020, Dr. Wessel entered into a Separation and Severance Agreement with the Company. Pursuant to the terms of the agreement, the Company agreed to pay Dr. Wessel severance of $237,500 in accordance with his employment contract. In addition, Dr. Wessel’s options granted under the Company’s 2014 Stock Option and Equity Incentive Plan continued to vest until June 30, 2021. Dr. Wessel shall have until December 31, 2021 to exercise his vested options and he shall be allowed to use a cashless exercise provision to exercise his vested options. The agreement also contains customary confidentiality, release, and non-disparagement provisions, and the Company agreed to pay accrued vacation time totaling approximately $28,940.

Other Postretirement Benefit Pl

Other Postretirement Benefit Plan	12 Months Ended
	Dec. 31, 2020
Retirement Benefits [Abstract]
OTHER POSTRETIREMENT BENEFIT PLAN	NOTE 12 - OTHER POSTRETIREMENT BENEFIT PLAN Relmada participates in a multiemployer 401(k) plan that permits eligible employees to contribute funds on a pretax basis subject to maximum allowed under federal tax provisions. The Company matches 100% of the first 3% of employee contributions, plus 50% of employee contributions that exceed 3% but do not exceed 5%. The employees choose an amount from various investment options for both their contributions and the Company’s matching contribution. The Company’s contribution expense was $90,692, $20,081, $10,261, and $18,853 for the year ended December 31, 2020 and December 31, 2019 (unaudited), the six months ended December 31, 2019 and year ended June 30, 2019, respectively.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 13 - SUBSEQUENT EVENTS From January 1 st From January 1 st On January 7, 2021, the Company awarded a total of 1,490,000 options to employees and board of directors at an exercise price of $33.43 and a 10-year term vesting over a four-year period. The grants to the employees are 50% based on a four year vesting term and the other 50% are based on milestones achieved. On January 7, 2021, the Company awarded Drs. Manfredi and Pappagallo, Acting CSO and Acting CMO, respectively, 200,000 warrants each, with an exercise price of $33.43 per share and a duration of 10 years from 1/7/2021. Half of each award shall vest 6.25% per quarter starting 4/7/21. The other half of each award shall vest 25% on 1/7/22, then 6.25% per quarter, and shall be subject to the same forfeiture for contingencies as the management options. On February 3, 2021, the Company awarded a total of 25,000 options to a new employee with an exercise price of $34.47 and a 10-year term vesting over a four-year period. The Company’s lease agreement at 880 Third Avenue expired on December 31, 2020 and has been renewed for calendar year 2021. Included in this lease is additional office space on the 10 th th

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). The consolidated financial statements include the Company’s accounts and those of the Company’s wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation. On September 26, 2019, the Company’s Board of Directors approved a 1-to-4 reverse split of the Common Stock, which was effective on the NASDAQ Capital Market on September 30, 2019. As a result of the reverse stock split, every 4 shares of issued and outstanding common stock were converted into 1 share of issued and outstanding common stock, with all fractional shares rounded up to the nearest whole share, and the Company’s authorized share of common stock were reduced from 200,000,000 to 50,000,000 shares. All share and per share amounts have been retroactively restated to reflect this reverse stock split.
Change in Fiscal Year	Change in Fiscal Year The Company changed its fiscal year end to December 31 from June 30. The information for the year ended December 31, 2019 is presented for comparative purposes only and is unaudited.
Liquidity	Liquidity As shown in the accompanying financial statements, the Company incurred negative operating cash flows of $27,808,801 for the year ended December 31, 2020 and has an accumulated deficit of $179,315,303 from inception through December 31, 2020. Relmada has funded its past operations through equity raises and most recently in the year ended December 31, 2020, Relmada raised net proceeds from the sale of common stock of $19,791,644, $8,056,416 through the exercise of warrants and $735,514 through the exercise of options. Management believes that due to the recent equity raises completed and exercises of outstanding warrants and the current cash position on its balance sheet, it has obtained sufficient funding to continue ongoing operations for at least 12 months from the issuance of this annual report. Since December 31, 2020 and to date, the Company has received approximately $1,909,200 in warrant and option exercises, which resulted in the Company having approximately $105.3 million in cash, cash equivalents, and short term investments at March 15, 2021. Based on its budgeted cash flow requirements, the Company believes these funds are sufficient to fund its ongoing operations for at least 12 months after the issuance of these consolidated financial statements. Regardless of the results of any ongoing clinical trial, the Company has control over its expenditures and has the ability to adjust spending accordingly based on the budgeted cash flow requirements developed and the excess cash on hand. Management believes that their existing cash and cash equivalents will enable them to fund operating expenses and capital expenditure requirements for at least the next 12 months from the issuance of these consolidated financial statements. Beyond that point management will evaluate the size and scope of any subsequent trials that will affect the timing of additional financings through public or private sales of equity or debt securities or from bank or other loans or through strategic collaboration and/or licensing agreements. Any such expenditures related to any subsequent trials will not be incurred until such additional financing is raised. Further, additional financing related to subsequent trials does not affect the Company’s conclusion that based on the cash on hand and the budgeted cash flow requirements, the Company has sufficient funds to maintain operations for at least 12 months from the issuance of these consolidated financial statements.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates. The significant estimates are stock-based compensation expenses, the valuation of derivative liabilities and recorded amounts related to income taxes.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers cash deposits and all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company’s cash deposits are held at two high-credit-quality financial institutions. The Company’s cash deposits of $2,495,397 at December 31, 2020 at these institutions exceed federally insured limits.
Short-term Investments	Short-term Investments The Company’s investments consist entirely of mutual funds. The securities are measured at fair value based on the net asset value (“NAV”). The Company has adopted FASB ASU 2016-01, Financial Instruments, for the year ended December 31, 2020 which requires substantially all equity investments in nonconsolidated entities to be measured at fair value with recurring changes recognized in earnings, except for those accounted for using equity method accounting. Changes in fair value of the securities are recorded as part of other income on the consolidated statement of operations. Short term investment activity is presented in the investing activities section on the consolidated statement of cash flows. Short-term investments at December 31, 2020 consisted of mutual funds with a fair value of $114,595,525.
Patents	Patents Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.
Fixed Assets	Fixed Assets Fixed assets are stated at cost less accumulated depreciation. Fixed assets are comprised of computers and software. Depreciation is calculated using the straight-line method over the estimated useful life of the assets. Computers and software have an estimated useful life of three years. Furniture and fixtures have an estimated useful life of approximately seven years.
Leases	Leases The Company recognizes their leases with a term of greater than a year on the balance sheet by recording right-of-use assets and lease liabilities. Leases can be classified as either operating leases or finance leases. Operating leases will result in straight-line lease expense, while finance leases will result in front-loaded expense. The Company’s lease consists of an operating leases for office space. The Company does not recognize a lease liability or right-of-use asset on the balance sheet for short-term leases. Instead, the Company recognizes short-term lease payments as an expense on a straight-line basis over the lease term. A short-term lease is defined as a lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s financial instruments primarily include cash, short term investments derivative liabilities and accounts payable. Due to the short-term nature of cash and accounts payable the carrying amounts of these assets and liabilities approximate their fair value. Derivatives are recorded at fair value at each period end. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows: Level 1 Inputs - Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 Inputs - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means. Level 3 Inputs - Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity). The Company’s short-term investment instruments of $114,595,525 at December 31, 2020 are classified using Level 1 inputs within the fair value hierarchy because they are valued using NAV. Unrealized gains and losses are recorded in the consolidated statement of operations as unrealized gain on short-term investments. The Company recorded an unrealized gain of $139,267, included in other income for the period ended December 31, 2020.
Fair Value on a Recurring Basis	Fair Value on a Recurring Basis As required by Accounting Standard Codification (ASC) Topic No. 820 - 10 Fair Value Measurement
Income Taxes	Income Taxes The Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in the tax rate is recognized in income or expense in the period that the change is effective. Tax benefits are recognized when it is probable that the deduction will be sustained. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will either expire before the Company is able to realize the benefit, or that future deductibility is uncertain. At December 31, 2020 and 2019 and June 30, 2019, the Company had recorded a valuation allowance to the full extent of the Company’s net deferred tax assets since the likelihood of realization of the benefit does not meet the more likely than not threshold. The Company files a U.S. Federal income tax return and various state returns. Uncertain tax positions taken on our tax returns will be accounted for as liabilities for unrecognized tax benefits. The Company will recognize interest and penalties, if any, related to unrecognized tax benefits in general and administrative expenses in the statements of operations. There were no liabilities recorded for uncertain tax positions at December 31, 2020 and 2019, and June 30, 2019. The open tax years, subject to potential examination by the applicable taxing authority, for the Company are from June 30, 2018 forward.
Research and Development	Research and Development Research and development costs primarily consist of research contracts for the advancement of product development, salaries and benefits, stock-based compensation, and consultants. The Company expenses all research and development costs in the period incurred. The Company makes an estimate of costs in relation to clinical study contracts. The Company analyzes the progress of studies, including the progress of clinical studies and phases, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability.
Stock-Based Compensation	Stock-Based Compensation The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period during which an employee is required to provide service in exchange for the award - the requisite service period. The grant-date fair value of employee share options is estimated using the Black-Scholes option pricing model adjusted for the unique characteristics of those instruments.
Net Loss per Common Share	Net Loss per Common Share Basic net loss per common share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per common share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of Class A convertible preferred stock, Series A preferred stock, restricted stock awards, options and warrants to purchase common stock. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net losses in each period. The potentially dilutive securities that would be anti-dilutive due to the Company’s net loss are not included in the calculation of diluted net loss per share attributable to common stockholders. The anti-dilutive securities are as follows (in common stock equivalent shares): Year ended (Unaudited) Year ended Six Months Year ended 2020 2019 2019 2019 Common stock warrants 2,670,633 3,646,872 3,646,872 4,429,982 Common stock options 3,905,737 3,615,602 3,615,602 1,473,314 Total 6,576,370 7,262,474 7,262,474 5,903,296
Recent Accounting Pronouncements	Recent Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, “ Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes In August 2018, FASB issued ASU 2018-13, Fair Value Measurement – Disclosure Framework (Topic 820). In November 2018, FASB issued ASU 2018-18 – Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Schedule of anti-dilutive securities	Year ended (Unaudited) Year ended Six Months Year ended 2020 2019 2019 2019 Common stock warrants 2,670,633 3,646,872 3,646,872 4,429,982 Common stock options 3,905,737 3,615,602 3,615,602 1,473,314 Total 6,576,370 7,262,474 7,262,474 5,903,296

Prepaid Expenses (Tables)

Prepaid Expenses (Tables)	12 Months Ended
	Dec. 31, 2020
Prepaid Expenses [Abstract]
Schedule of prepaid expenses	December 31, December 31, June 30, Insurance $ 527,600 $ 223,600 $ 451,500 Research and Development 291,800 139,200 - Legal 11,000 11,000 7,500 Other 72,800 50,100 61,800 Total $ 903,200 $ 423,900 $ 520,800

Fixed Assets (Tables)

Fixed Assets (Tables)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Schedule of fixed assets	Useful lives December 31, December 31, June 30, Computer and software 3 years $ 16,700 $ 16,700 $ 16,700 Less: accumulated depreciation (15,400 ) (11,700 ) (9,500 ) Fixed assets, net $ 1,300 $ 5,000 $ 7,200

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2020
Payables and Accruals [Abstract]
Schedule of accrued expenses	December 31, December 31, June 30, Research and development $ 2,183,800 $ 134,500 $ 563,400 Professional fees 150,900 172,900 98,400 Accrued bonus 1,444,900 50,000 - Accrued vacation 351,200 124,600 96,700 Legal Settlement - 250,000 500,000 Other 126,200 92,900 59,400 Total $ 4,257,000 $ 824,900 $ 1,317,900

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	12 Months Ended
	Dec. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of reconciliation of changes in the fair value of financial liabilities	Year ended Six months ended Year ended (Unaudited) December 31, December 31, December 31, June 30, 2020 2019 2019 2019 Beginning balance $ - $ - $ - $ 4,194,634 Adoption of ASU 2017-11 – warrants - - - (59,397 ) Fair value of derivative liabilities for redemption feature of promissory notes payable - - - - Change in fair value of derivative liabilities - - - 54,634 Extinguishment of derivative liabilities on conversion of promissory notes. - - - (4,189,871 ) Ending balance $ - $ - $ - $ -

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2020
Stockholders' Equity (Tables) [Line Items]
Schedule of private placements of securities pursuant to unit purchase agreements and subscription agreements	Date of closing Common Stock Issued Warrants issued Unit Price Net proceeds Warrant exercise price Warrant coverage October 12, 2018 501,027 325,668 $ 3.60 $ 1,630,991 $ 6.00 .65 October 18, 2018 410,084 266,555 $ 3.60 $ 1,287,007 $ 6.00 .65 November 2, 2018 374,864 243,662 $ 3.60 $ 1,215,242 $ 6.00 .65 December 5, 2018 334,694 217,550 $ 3.60 $ 1,083,307 $ 6.00 .65 February 12, 2019 201,389 130,903 $ 3.60 $ 725,000 $ 6.00 .65 March 27, 2019 178,572 89,286 $ 5.60 $ 1,000,000 $ 9.00 .50 May 14, 2019 569,083 284,541 $ 6.00 $ 3,168,865 $ 9.00 .50 June 14, 2019 612,914 306,456 $ 6.00 $ 3,274,331 $ 9.00 .50 June 20, 2019 720,799 360,399 $ 6.00 $ 4,059,050 $ 9.00 .50 June 28, 2019 71,689 35,845 $ 6.00 $ 395,863 $ 9.00 .50 Total 3,975,115 2,260,865 $ 17,839,656
Schedule of Black-Scholes option pricing model assumptions	(Unaudited) Years Ended Years Ended Six Months ended Year ended December 31, December 31, December 31, June 30, 2020 2019 2019 2019 Risk free interest rate 0.36 to 0.83 % 1.73 to 2.37 % 1.73 to 1.79 % 2.37 to 2.69 % Dividend yield 0 % 0 % 0 % 0 % Volatility 101-108 % 101.5-108 % 107.4-108.2 % 101.5-102.3 % Expected term (in years) 6.25 5 to 6.25 5 to 6.25 6.25
Schedule of stock-based compensation expense	(Unaudited) Year Year Six Months ended Year ended December 31, December 31, December 31, June 30, 2020 2019 2019 2019 Research and development $ 4,038,500 $ 360,900 $ 174,500 $ 215,900 General and administrative 16,738,800 2,804,300 2,192,500 998,100 Total $ 20,777,300 $ 3,165,200 $ 2,367,000 $ 1,214,000
Warrants [Member]
Stockholders' Equity (Tables) [Line Items]
Schedule of changes in outstanding warrants	Number of Shares Weighted Average Exercise Price Per Share Outstanding at June 30, 2018 2,453,757 $ 15.845 Issued 2,691,123 $ 7.10 Exercised (25,004 ) $ 0.004 Forfeited/Expired (689,894 ) $ 18.94 Outstanding at June 30, 2019 4,429,982 $ 7.12 Issued 21,250 $ 10.25 Exercised (740,694 ) $ 7.80 Forfeited/Expired (63,666 ) $ 13.89 Outstanding at December 31, 2019 3,646,872 $ 6.83 Issued 250,000 $ 33.32 Exercised (1,211,199 ) $ 7.27 Forfeited/Expired (15,040 ) $ 16.80 Outstanding at December 31, 2020 2,670,633 $ 9.11 Warrants exercisable at December 31, 2020 2,646,257 $ 9.16
Option Outstanding [Member]
Stockholders' Equity (Tables) [Line Items]
Schedule of changes in outstanding warrants	Number of Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term Aggregate Intrinsic Outstanding and expected to vest at June 30, 2018 767,220 $ 5.80 8.8 $ 511,000 Granted 712,500 4.73 9.5 - Forfeited (6,406 ) - - - Outstanding and expected to vest at June 30, 2019 1,473,314 $ 5.18 8.6 $ 4,668,153 Granted 2,205,000 29.32 9.8 - Exercised (62,712 ) - - $ - Outstanding and expected to vest at December 31, 2019 3,615,602 $ 19.96 9.2 $ 74,837,043 Granted 1,000,000 39.50 9.3 - Exercised (253,927 ) - - - Forfeited (455,938 ) - - - Outstanding and expected to vest at December 31, 2020 3,905,737 $ 24.32 8.4 $ 48,952,339 Options exercisable at December 31, 2020 1,241,359 $ 16.73 7.7 $ 22,960,117

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of deferred tax assets	December 31, December 31, June 30, Deferred tax assets: Federal net operating loss $ 15,227,000 $ 13,022,000 $ 13,555,000 State net operating loss 9,361,000 7,912,000 8,252,000 Research and development tax credits 3,407,000 1,499,000 1,230,000 Capitalized R&D 14,387,000 3,168,000 - Nonqualified Stock Options 7,352,000 172,000 - Accruals 645,000 133,000 206,000 Other 41,000 45,000 46,000 Less: valuation allowance (50,420,000 ) (25,951,000 ) (23,289,000 ) Total $ - $ - $ -
Schedule of reconciliation of the statutory tax rate to the effective tax rate	Year Ended (Unaudited) Six Months Ended Year Ended Statutory federal income tax rate 21.00 % 21.00 % 21 % 21 % State (net of federal benefit) 15.50 % 16.21 % 11.96 % 9.5 % Non-deductible expenses 0.42 % (4.24 )% (5.75 )% (6.3 )% R&D Credit 3.21 % 3.02 % - % - % Other 1.01 % 1.08 % 5.27 % 1 % Change in valuation allowance (41.15 )% (37.07 )% (32.48 )% (25.2 )% Effective income tax rate 0 % 0 % 0 % 0 %

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Schedule of future minimum lease payments to be received	2021 $ 90,348 2022 90,348 Total $ 180,696

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	1 Months Ended	6 Months Ended	12 Months Ended
	Sep. 26, 2019	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2019	Mar. 15, 2021
Summary of Significant Accounting Policies (Details) [Line Items]
Description of reverse stock split	the Company’s Board of Directors approved a 1-to-4 reverse split of the Common Stock, which was effective on the NASDAQ Capital Market on September 30, 2019. As a result of the reverse stock split, every 4 shares of issued and outstanding common stock were converted into 1 share of issued and outstanding common stock, with all fractional shares rounded up to the nearest whole share, and the Company’s authorized share of common stock were reduced from 200,000,000 to 50,000,000 shares. All share and per share amounts have been retroactively restated to reflect this reverse stock split.
Negative operating cash flows activities			$ 27,808,801
Accumulated deficit		$ (119,858,909)	(179,315,303)	$ (119,858,909)	$ (111,662,367)
Proceeds from sale of common stock			19,791,644
Proceeds from warrants exercised for common stock		4,447,038	8,056,416	4,447,038
Proceeds from options exercised for common stock			735,514
Warrant and option exercises received			1,909,200
Cash deposits			2,495,397
Short-term investments		80,164,823	114,595,525	80,164,823
Unrealized gain			139,267
Subsequent Event [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Cash						$ 105.3
Level 1 [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Short-term investments			$ 114,595,525
Computers and Software [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Fixed assets, estimated useful life			3 years
Furniture and Fixtures [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Fixed assets, estimated useful life			7 years

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of anti-dilutive securities - shares	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	7,262,474	6,576,370	7,262,474	5,903,296
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	3,646,872	2,670,633	3,646,872	4,429,982
Common stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	3,615,602	3,905,737	3,615,602	1,473,314

Prepaid Expenses (Details) - Sc

Prepaid Expenses (Details) - Schedule of prepaid expenses - USD ($)	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2019
Schedule of prepaid expenses [Abstract]
Insurance	$ 527,600	$ 223,600	$ 451,500
Research and Development	291,800	139,200
Legal	11,000	11,000	7,500
Other	72,800	50,100	61,800
Total	$ 903,200	$ 423,900	$ 520,800

Fixed Assets (Details) - Schedu

Fixed Assets (Details) - Schedule of fixed assets - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2019
Property, Plant and Equipment [Line Items]
Computer and software	$ 16,700	$ 16,700	$ 16,700
Less: accumulated depreciation	(15,400)	(11,700)	(9,500)
Fixed assets, net	$ 1,300	$ 5,000	$ 7,200
Computer and Software [Member]
Property, Plant and Equipment [Line Items]
Useful lives	3 years

Accrued Expenses (Details) - Sc

Accrued Expenses (Details) - Schedule of accrued expenses - USD ($)	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2019
Schedule of accrued expenses [Abstract]
Research and development	$ 2,183,800	$ 134,500	$ 563,400
Professional fees	150,900	172,900	98,400
Accrued bonus	1,444,900	50,000
Accrued vacation	351,200	124,600	96,700
Legal Settlement		250,000	500,000
Other	126,200	92,900	59,400
Total	$ 4,257,000	$ 824,900	$ 1,317,900

Notes Payable (Details)

Notes Payable (Details) - USD ($)	1 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2020	Dec. 31, 2019
Debt Disclosure [Abstract]
Note payable, conjunction of director and officer	$ 364,200	$ 285,200
Note payable, interest rate per annum	3.09%	2.35%
Note matured	Apr. 9, 2020	Apr. 9, 2019
Note payable, outstanding balance	$ 364,200		$ 0	$ 110,200

Derivative Liabilities (Details

Derivative Liabilities (Details) - Schedule of reconciliation of changes in the fair value of financial liabilities - USD ($)	6 Months Ended		12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2019	Jun. 30, 2019
Schedule of reconciliation of changes in the fair value of financial liabilities [Abstract]
Beginning balance				$ 4,194,634
Adoption of ASU 2017-11 – warrants				(59,397)
Fair value of derivative liabilities for redemption feature of promissory notes payable
Change in fair value of derivative liabilities				54,634
Extinguishment of derivative liabilities on conversion of promissory notes.				(4,189,871)
Ending balance

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	Dec. 16, 2020	Apr. 01, 2020	Oct. 08, 2019	Apr. 01, 2019	Mar. 09, 2019	Jan. 02, 2019	Oct. 12, 2018	Apr. 27, 2020	Dec. 19, 2019	Aug. 01, 2019	Dec. 20, 2018	Oct. 18, 2018	Dec. 31, 2014	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2019	May 15, 2020
Stockholders' Equity (Details) [Line Items]
Common stocks issued (in Shares)														42,644	42,475		24,991
Shares issued for cashless exercise of warrants (in Shares)														88,751	60,513	88,751	25,004
Exercise of warrants (in Dollars)														$ 4,447,038
Cashless exercise of option (in Shares)														67,578			98,370
Issuance of common stock for exercise (in Shares)															155,558
Common stock exercise options for proceeds (in Dollars)															$ 735,514
Deferred Offering Costs (in Dollars)																		$ 75,000,000
Stock Issued During Period, Shares, Other (in Shares)															19,791,644
Description of private placement														the Company closed on a private placement of 3,833,334 shares of common stock. The price per share was $30.00 to the public (with a price to the underwriters of $28.00 per share). The net proceeds from the closing was $108,621,733. Approximately, $478,000 of legal and professional fees were incurred in relation to the closing. The Company also closed on a private placement of 117,965 shares for $7.00 per share and net proceeds of $825,749 during the 3rd calendar quarter of 2019.
Agreement description																	the Company closed on private placements of securities pursuant to Unit Purchase Agreements and Subscription Agreements, each dated as shown below. The price per unit (comprising one common stock and a 5 year warrant to purchase 2.60 or 2.00 of a share of common stock) was $3.60, $5.60 or $6.00. The Company issued an aggregate of 3,975,115 shares of common stock to investors in these closings, for net proceeds of $17,839,656. Approximately $79,000 of legal costs were incurred that were not allocated to the individual closings.
Other receivable (in Dollars)																	$ 177,000
Percentage of convertible promissory notes							7.00%					7.00%
Converted shares of common stock (in Shares)							2,682,917					2,682,917
Expected life term															6 years 3 months		6 years 3 months
Expected dividends rate														0.00%	0.00%	0.00%	0.00%
Stock options exercisable period													10 years
Shares available for future grants (in Shares)															1,247,205
Additional compensation expense (in Dollars)														$ 2,367,001	$ 20,777,272		$ 1,213,996
Total expense (in Dollars)															1,800,000
Unrecognized stock-based compensation expense (in Dollars)															$ 53,502,000
Unvested stock options weighted average remaining service period															3 years 14 days
Weighted average fair value of options granted (in Dollars per share)														$ 24.31	$ 32.45	$ 24	$ 3.84
Warrants expired (in Shares)																	643,643
Minimum [Member]
Stockholders' Equity (Details) [Line Items]
Expected life term														5 years		5 years
Discount rate														1.73%	0.36%	1.73%	2.37%
Expected volatility rate														107.40%	101.00%	101.50%	101.50%
Maximum [Member]
Stockholders' Equity (Details) [Line Items]
Expected life term														6 years 3 months		6 years 3 months
Discount rate														1.79%	0.83%	2.37%	2.69%
Expected volatility rate														108.20%	108.00%	108.00%	102.30%
Stock Option and Equity Incentive Plan [Member]
Stockholders' Equity (Details) [Line Items]
Expected life term				6 years 3 months							6 years 3 months
Aggregate fair value of options (in Dollars)				$ 214,000
Discount rate				2.37%							2.69%
Expected volatility rate				101.50%							102.30%
Expected dividends rate				0.00%							0.00%
Number of options granted (in Shares)				37,500									5,152,942
Description of employees options									The options have a ten-year term and have an exercise price of $43.47 and vest over 4 years. The options have an aggregate fair value of $46,904,043 calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 1.79% (2) expected life of 6.25 years, (3) expected volatility of 108.2%, and (4) zero expected dividends.		the Company granted various employees options to purchase a total of 675,000 shares of common stock. The options have a ten-year term and have an exercise price of $4.60 and vest over 4 years. The options have an aggregate fair value of $2,500,000 calculated using the Black-Scholes option-pricing model.				the Company awarded a total of 1,000,000 options to employees with exercise prices ranging from $28.00- $45.61 and a 10-year term vesting over 4-year period. The options have an aggregate fair value of $32.4 million calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 0.36%-0.83% (2) expected life of 6.25 years, (3) expected volatility of 101%-108%, and (4) zero expected dividends.
Additional compensation expense (in Dollars)															$ 1,500,000
Compensation expense (in Dollars)															484,000
Stock options term, description				The options have a ten-year term and have an exercise price of $7.04 and vest over 4 years.
Options exercise price (in Dollars per share)				$ 7.04
Vesting period				4 years
Stock Option And Equity Incentive Plan One [Member]
Stockholders' Equity (Details) [Line Items]
Description of employees options									the Company granted a consultant options to purchase a total of 10,000 shares of common stock. The options have a ten-year term and have an exercise price of $43.47 and vest immediately. The options have an aggregate fair value of $338,992 calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 1.73% (2) expected life of 5 years, (3) expected volatility of 107.4%, and (4) zero expected dividends.
Stock-based compensation - warrants [Member]
Stockholders' Equity (Details) [Line Items]
Unrecognized stock-based compensation expense (in Dollars)															3,400,000
Aggregate intrinsic value of warrants vested and outstanding (in Dollars)															61,200,000
Placement Agent [Member]
Stockholders' Equity (Details) [Line Items]
Expected life term																	5 years
Aggregate fair value of options (in Dollars)																	$ 1,809,535
Expected dividends rate																	0.00%
Placement Agent [Member] | Minimum [Member]
Stockholders' Equity (Details) [Line Items]
Exercise price per share (in Dollars per share)																	$ 3.96
Discount rate																	1.74%
Expected volatility rate																	100.70%
Placement Agent [Member] | Maximum [Member]
Stockholders' Equity (Details) [Line Items]
Exercise price per share (in Dollars per share)																	$ 9
Expected volatility rate																	103.40%
Consultant [Member]
Stockholders' Equity (Details) [Line Items]
Expected life term	3 years 9 months	2 years 6 months			5 years			2 years 6 months
Aggregate fair value of options (in Dollars)	$ 479,000	$ 2,500,000			$ 95,131			$ 48,000
Discount rate	0.37%	0.26%			2.42%			0.27%
Expected volatility rate	105.00%	118.00%			102.00%			116.00%
Expected dividends rate	0.00%	0.00%			0.00%			0.00%
Number of options granted (in Shares)	20,000	120,000			17,857			2,000
Stock options term, description					the Company granted 17,857 warrants to a consultant with an exercise price of $7.00, a 5-year term and immediate vesting.
Options exercise price (in Dollars per share)	$ 34.87	$ 31.59			$ 7			$ 37.67
Vesting period	4 years
Consultant One [Member]
Stockholders' Equity (Details) [Line Items]
Expected life term	5 years
Aggregate fair value of options (in Dollars)	$ 2,860,000
Discount rate	0.37%
Expected volatility rate	105.00%
Expected dividends rate	0.00%
Number of options granted (in Shares)	108,000
Stock options term, description	On December 16, 2020, the Company granted 108,000 warrants to consultants with an exercise price of $34.87, a 5-year term and vesting based on future events.
Options exercise price (in Dollars per share)	$ 34.87
Contractor [Member]
Stockholders' Equity (Details) [Line Items]
Expected life term			5 years			6 years 3 months				5 years	6 years 3 months
Aggregate fair value of options (in Dollars)			$ 121,252			$ 112,183				$ 41,386	$ 93,762
Discount rate			1.36%			2.49%				1.68%	2.69%
Expected volatility rate			100.00%			102.00%				101.10%	102.30%
Expected dividends rate			0.00%			0.00%				0.00%	0.00%
Number of options granted (in Shares)			15,000			30,000				6,250	25,000
Stock options term, description						On January 1, 2019, the Company granted 30,000 warrants to a contractor with an exercise price of $4.60, a 10-year term and quarterly vesting over four years vesting.				On August 1, 2019, the Company granted 6,250 warrants to a contractor with an exercise price of $8.80, a 10-year term and immediate vesting.	the Company granted 25,000 warrants to a contractor with an exercise price of $4.60, a 10-year term and immediate vesting.
Options exercise price (in Dollars per share)			$ 10.85			$ 4.60				$ 8.80	$ 4.60
Vesting period						4 years
Investors [Member]
Stockholders' Equity (Details) [Line Items]
Expected life term																	5 years
Aggregate fair value of options (in Dollars)																	$ 11,420,300
Expected dividends rate																	0.00%
Warrant, granted (in Shares)																	2,260,860
Investors [Member] | Minimum [Member]
Stockholders' Equity (Details) [Line Items]
Exercise price per share (in Dollars per share)																	$ 6
Discount rate																	1.74%
Expected volatility rate																	100.70%
Investors [Member] | Maximum [Member]
Stockholders' Equity (Details) [Line Items]
Exercise price per share (in Dollars per share)																	$ 9
Expected volatility rate																	103.40%
Stock-based compensation - warrants [Member]
Stockholders' Equity (Details) [Line Items]
Common stocks issued (in Shares)
Exercise of warrants (in Dollars)															8,056,416
Stock-based compensation - warrants [Member] | Placement Agent [Member]
Stockholders' Equity (Details) [Line Items]
Warrants issued to placement agent, share (in Shares)																	357,396
Common Stock [Member]
Stockholders' Equity (Details) [Line Items]
Common stocks issued (in Shares)														61,484			90,204
Stock Issued During Period, Shares, Other (in Shares)														3,951,299			3,975,115
Additional compensation expense (in Dollars)

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Schedule of private placements of securities pursuant to unit purchase agreements and subscription agreements	12 Months Ended
	Dec. 31, 2020USD ($)$ / sharesshares
Stockholders' Equity (Details) - Schedule of private placements of securities pursuant to unit purchase agreements and subscription agreements [Line Items]
Common Stock Issued (in Dollars) | $	$ 3,975,115
Warrants issued (in Shares) | shares	2,260,865
Net proceeds (in Dollars) | $	$ 17,839,656
October 12, 2018 [Member]
Stockholders' Equity (Details) - Schedule of private placements of securities pursuant to unit purchase agreements and subscription agreements [Line Items]
Common Stock Issued (in Dollars) | $	$ 501,027
Warrants issued (in Shares) | shares	325,668
Unit Price	$ 3.60
Net proceeds (in Dollars) | $	$ 1,630,991
Warrant exercise price	$ 6
Warrant coverage	$ 0.65
October 18, 2018 [Member]
Stockholders' Equity (Details) - Schedule of private placements of securities pursuant to unit purchase agreements and subscription agreements [Line Items]
Common Stock Issued (in Dollars) | $	$ 410,084
Warrants issued (in Shares) | shares	266,555
Unit Price	$ 3.60
Net proceeds (in Dollars) | $	$ 1,287,007
Warrant exercise price	$ 6
Warrant coverage	$ 0.65
November 2, 2018 [Member]
Stockholders' Equity (Details) - Schedule of private placements of securities pursuant to unit purchase agreements and subscription agreements [Line Items]
Common Stock Issued (in Dollars) | $	$ 374,864
Warrants issued (in Shares) | shares	243,662
Unit Price	$ 3.60
Net proceeds (in Dollars) | $	$ 1,215,242
Warrant exercise price	$ 6
Warrant coverage	$ 0.65
December 5, 2018 [Member]
Stockholders' Equity (Details) - Schedule of private placements of securities pursuant to unit purchase agreements and subscription agreements [Line Items]
Common Stock Issued (in Dollars) | $	$ 334,694
Warrants issued (in Shares) | shares	217,550
Unit Price	$ 3.60
Net proceeds (in Dollars) | $	$ 1,083,307
Warrant exercise price	$ 6
Warrant coverage	$ 0.65
February 12, 2019 [Member]
Stockholders' Equity (Details) - Schedule of private placements of securities pursuant to unit purchase agreements and subscription agreements [Line Items]
Common Stock Issued (in Dollars) | $	$ 201,389
Warrants issued (in Shares) | shares	130,903
Unit Price	$ 3.60
Net proceeds (in Dollars) | $	$ 725,000
Warrant exercise price	$ 6
Warrant coverage	$ 0.65
March 27, 2019 [Member]
Stockholders' Equity (Details) - Schedule of private placements of securities pursuant to unit purchase agreements and subscription agreements [Line Items]
Common Stock Issued (in Dollars) | $	$ 178,572
Warrants issued (in Shares) | shares	89,286
Unit Price	$ 5.60
Net proceeds (in Dollars) | $	$ 1,000,000
Warrant exercise price	$ 9
Warrant coverage	$ 0.50
May 14, 2019 [Member]
Stockholders' Equity (Details) - Schedule of private placements of securities pursuant to unit purchase agreements and subscription agreements [Line Items]
Common Stock Issued (in Dollars) | $	$ 569,083
Warrants issued (in Shares) | shares	284,541
Unit Price	$ 6
Net proceeds (in Dollars) | $	$ 3,168,865
Warrant exercise price	$ 9
Warrant coverage	$ 0.50
June 14, 2019 [Member]
Stockholders' Equity (Details) - Schedule of private placements of securities pursuant to unit purchase agreements and subscription agreements [Line Items]
Common Stock Issued (in Dollars) | $	$ 612,914
Warrants issued (in Shares) | shares	306,456
Unit Price	$ 6
Net proceeds (in Dollars) | $	$ 3,274,331
Warrant exercise price	$ 9
Warrant coverage	$ 0.50
June 20, 2019 [Member]
Stockholders' Equity (Details) - Schedule of private placements of securities pursuant to unit purchase agreements and subscription agreements [Line Items]
Common Stock Issued (in Dollars) | $	$ 720,799
Warrants issued (in Shares) | shares	360,399
Unit Price	$ 6
Net proceeds (in Dollars) | $	$ 4,059,050
Warrant exercise price	$ 9
Warrant coverage	$ 0.50
June 28, 2019 [Member]
Stockholders' Equity (Details) - Schedule of private placements of securities pursuant to unit purchase agreements and subscription agreements [Line Items]
Common Stock Issued (in Dollars) | $	$ 71,689
Warrants issued (in Shares) | shares	35,845
Unit Price	$ 6
Net proceeds (in Dollars) | $	$ 395,863
Warrant exercise price	$ 9
Warrant coverage	$ 0.50

Stockholders' Equity (Details_2

Stockholders' Equity (Details) - Schedule of changes in options outstanding - Options [Member] - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2020	Jun. 30, 2019
Stockholders' Equity (Details) - Schedule of changes in options outstanding [Line Items]
Number of Shares, Outstanding and expected to vest, Beginning balance	1,473,314	3,615,602	767,220
Weighted Average Exercise Price Per Share, Outstanding and expected to vest - Beginning balance	$ 5.18	$ 19.96	$ 5.80
Weighted Average Remaining Contractual Term (Years), Beginning Outstanding			8 years 292 days
Aggregate Intrinsic Value, Outstanding and expected to vest - Beginning balance	$ 4,668,153	$ 74,837,043	$ 511,000
Number of Shares, Granted	2,205,000	1,000,000	712,500
Weighted Average Exercise Price Per Share, Granted	$ 29.32	$ 39.50	$ 4.73
Weighted Average Remaining Contractual Term (Years), Granted	9 years 292 days	9 years 109 days	9 years 6 months
Aggregate Intrinsic Value, Outstanding and expected to vest, Granted
Number of Shares, Exercised	(62,712)	(253,927)
Weighted Average Exercise Price Per Share, Exercised
Weighted Average Remaining Contractual Term (Years), Exercised
Aggregate Intrinsic Value, Outstanding and expected to vest, Exercised
Number of Shares, Forfeited		(455,938)	(6,406)
Weighted Average Exercise Price Per Share, Forfeited
Weighted Average Remaining Contractual Term (Years), Forfeited
Aggregate Intrinsic Value, Outstanding and expected to vest, Forfeited
Number of Shares, Outstanding and expected to vest, Ending balance	3,615,602	3,905,737	1,473,314
Weighted Average Exercise Price Per Share, Outstanding and expected to vest - Ending balance	$ 19.96	$ 24.32	$ 5.18
Weighted Average Remaining Contractual Term (Years), Ending Outstanding	9 years 73 days	8 years 146 days	8 years 219 days
Aggregate Intrinsic Value, Outstanding and expected to vest - Ending balance	$ 74,837,043	$ 48,952,339	$ 4,668,153
Number of Shares, Options exercisable		1,241,359
Weighted Average Exercise Price Per Share, Options exercisable		$ 16.73
Weighted Average Remaining Contractual Term (Years), Options exercisable		7 years 255 days
Aggregate Intrinsic Value, Options exercisable		$ 22,960,117

Stockholders' Equity (Details_3

Stockholders' Equity (Details) - Schedule of Black-Scholes option pricing model assumptions	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2019
Stockholders' Equity (Details) - Schedule of Black-Scholes option pricing model assumptions [Line Items]
Dividend yield	0.00%	0.00%	0.00%	0.00%
Expected term (in years)		6 years 3 months		6 years 3 months
Minimum [Member]
Stockholders' Equity (Details) - Schedule of Black-Scholes option pricing model assumptions [Line Items]
Risk free interest rate	1.73%	0.36%	1.73%	2.37%
Volatility	107.40%	101.00%	101.50%	101.50%
Expected term (in years)	5 years		5 years
Maximum [Member]
Stockholders' Equity (Details) - Schedule of Black-Scholes option pricing model assumptions [Line Items]
Risk free interest rate	1.79%	0.83%	2.37%	2.69%
Volatility	108.20%	108.00%	108.00%	102.30%
Expected term (in years)	6 years 3 months		6 years 3 months

Stockholders' Equity (Details_4

Stockholders' Equity (Details) - Schedule of changes in outstanding warrants - $ / shares	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2020	Jun. 30, 2019
Schedule of changes in outstanding warrants [Abstract]
Number of Shares, Outstanding, Ending balance	4,429,982	3,646,872	2,453,757
Weighted Average Exercise Price Per Share, Outstanding, Ending balance	$ 7.12	$ 6.83	$ 15.845
Number of Shares, Issued	21,250	250,000	2,691,123
Weighted Average Exercise Price Per Share, Issued	$ 10.25	$ 33.32	$ 7.10
Number of Shares, Exercised	(740,694)	(1,211,199)	(25,004)
Weighted Average Exercise Price Per Share, Exercised	$ 7.80	$ 7.27	$ 0.004
Number of Shares, Forfeited/Expired	(63,666)	(15,040)	(689,894)
Weighted Average Exercise Price Per Share, Forfeited/Expired	$ 13.89	$ 16.80	$ 18.94
Number of Shares, Outstanding, Ending balance	3,646,872	2,670,633	4,429,982
Weighted Average Exercise Price Per Share, Outstanding, Ending balance	$ 6.83	$ 9.11	$ 7.12
Number of Shares, Warrants exercisable		2,646,257
Weighted Average Exercise Price Per Share, Warrants exercisable		$ 9.16

Stockholders' Equity (Details_5

Stockholders' Equity (Details) - Schedule of stock-based compensation expense - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 2,367,000	$ 20,777,300	$ 3,165,200	$ 1,214,000
Research and development [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	174,500	4,038,500	360,900	215,900
General and administrative [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 2,192,500	$ 16,738,800	$ 2,804,300	$ 998,100

Income Taxes (Details)

Income Taxes (Details) - USD ($)	1 Months Ended	6 Months Ended	12 Months Ended
	Mar. 27, 2020	Dec. 31, 2019	Dec. 31, 2020	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Description of class life changes	the Coronavirus Aid Relief and Economic Security (“CARES”) Act was signed into law. The Act contains several new or changed income tax provisions, including but not limited to the following: increased limitation threshold for determining deductible interest expense, class life changes to qualified improvements (in general, from 39 years to 15 years) and the ability to carry back net operating losses (“NOLs”) incurred from tax years 2018 through 2020 up to the five preceding tax years. Most of these provisions are either not applicable or have no material effect on the Company.
Valuation allowance of assets		$ 4,357,000	$ 2,662,000	$ 24,469,000
Net operating loss carryforwards, description			the Company had federal, New York State and New York City net operating loss (NOL) carryforwards of approximately $72,507,000, $68,854,000 and $68,470,000 respectively, which begin expiring in 2027, 2032 and 2032 respectively. Approximately $27,037,000 federal NOL can be carried forward indefinitely but it is limited to 80% of future taxable income.
Federal tax credit carryforwards			$ 3,407,000

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of deferred tax assets - USD ($)	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2019
Schedule of deferred tax assets [Abstract]
Federal net operating loss	$ 15,227,000	$ 13,022,000	$ 13,555,000
State net operating loss	9,361,000	7,912,000	8,252,000
Research and development tax credits	3,407,000	1,499,000	1,230,000
Capitalized R&D	14,387,000	3,168,000
Nonqualified Stock Options	7,352,000	172,000
Accruals	645,000	133,000	206,000
Other	41,000	45,000	46,000
Less: valuation allowance	(50,420,000)	(25,951,000)	(23,289,000)
Total

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of reconciliation of the statutory tax rate to the effective tax rate	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2019
Schedule of reconciliation of the statutory tax rate to the effective tax rate [Abstract]
Statutory federal income tax rate	21.00%	21.00%	21.00%	21.00%
State (net of federal benefit)	11.96%	15.50%	16.21%	9.50%
Non-deductible expenses	(5.75%)	0.42%	(4.24%)	(6.30%)
Impact of Tax Cuts and Jobs Act		3.21%	3.02%
Other	5.27%	1.01%	1.08%	1.00%
Change in valuation allowance	(32.48%)	(41.15%)	(37.07%)	(25.20%)
Effective income tax rate	0.00%	0.00%	0.00%	0.00%

Commitments and Contingencies_2

Commitments and Contingencies (Details) - USD ($)	Feb. 06, 2019	Jan. 02, 2019	Jun. 08, 2017	Jun. 30, 2019	Jan. 31, 2018	Jun. 30, 2015	Aug. 20, 2007	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2019
Commitments and Contingencies (Details) [Line Items]
Cost of license						$ 16,600
Unearned interest income									$ 14,900	$ 32,100	$ 43,000
Description of settlement agreement	On February 6, 2019, the Company entered into a settlement agreement in which Babul relinquished his 303,392 shares in Relmada, signed a consulting contract and Relmada committed to a $500,000 initial payment and four subsequent payments of $250,000 on March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019.
Loss on settlement				$ 1,105,590
Cash payments				1,500,000
Fair value of relinquished				394,410
Licensing Agreements [Member]
Commitments and Contingencies (Details) [Line Items]
Description of rights granted to license agreement					In consideration of the rights granted to Relmada under the License Agreement, Relmada paid the Licensor an upfront, non-refundable license fee of $180,000. Additionally, Relmada will pay Licensor $45,000 every three months until the earliest to occur of the following events: (i) the first commercial sale of a licensed product anywhere in the world, (ii) the expiration or invalidation of the last to expire or be invalidated of the patent rights anywhere in the world, or (iii) the termination of the License Agreement. Relmada will also pay Licensor tiered royalties with a maximum rate of 2%, decreasing to 1.75%, and 1.5% in certain circumstances, on net sales of licensed products covered under the License Agreement. Relmada will also pay Licensor tiered payments up to a maximum of 20%, and decreasing to 17.5%, and 15% in certain circumstances, of all consideration received by Relmada for sublicenses granted under the License Agreement.
Rent expense		$ 7,500		$ 93,900				$ 114,800	$ 47,100	$ 165,900
FFE [Member]
Commitments and Contingencies (Details) [Line Items]
Description of lease agreement			Actinium will continue to license the furniture, fixtures, equipment and tenant improvements located in the office (FFE) for a license fee of $7,529 per month until December 8, 2022. Actinium shall have at any time during the term of this agreement the right to purchase the FFE for $496,914, less any previously paid license fees. The license of FFE qualifies as a sales-type lease. On June 8, 2017 the Company derecognized the underlying assets of $493,452, recognized discounted lease payments receivable of $397,049 using the discount rate of 8.38% and recognized loss on sales-type lease of fixed assets of $96,403.
Licensing Agreements [Member] | Wonpung [Member]
Commitments and Contingencies (Details) [Line Items]
Upfront license fee							$ 1,500,000
Net sales rate							12.00%
Description of lease agreement							The terms of each licensing agreement will expire on the earlier of any time from 15 years to 20 years after licensing or on the date of commercial availability of a generic product to such licensed product in the licensed territory.
Business acquisition, description							(A) royalty payments up to 2% on net sales of licensed products that are not sold by sublicensee and (B) on each and every sublicense earned royalty payment received by licensee from its sublicensee on sales of license product by sublicensee, the higher of (i) 20% of the royalties received by licensee; or (ii) up to 2% of net sales of sublicensee. The Company will also make milestone payments of up to $4 or $2 million, for the first commercial sale of product in the field that has a single active pharmaceutical ingredient, and for the first commercial sale of product in the field of product that has more than one active pharmaceutical ingredient, respectively. As of December 31, 2020, the Company has not generated any revenue related to this license agreement.

Commitments and Contingencies_3

Commitments and Contingencies (Details) - Schedule of future minimum lease payments to be received	Dec. 31, 2020USD ($)
Schedule of future minimum lease payments to be received [Abstract]
2021	$ 90,348
2022	90,348
Total	$ 180,696

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	Mar. 06, 2020	Dec. 31, 2020
Dr. Vitolo [Member]
Related Party Transactions (Details) [Line Items]
Description of agreement	Vitolo entered into a Separation and Severance Agreement with the Company. Pursuant to the terms of the agreement, the Company agreed to pay Dr. Vitolo severance of $200,000 in accordance with his employment contract. In addition, Dr. Vitolo’s options granted under the Company’s 2014 Stock Option and Equity Incentive Plan continued to vest until September 6, 2020. Dr. Vitolo shall have until March 6, 2021 to exercise his vested options and he shall be allowed to use a cashless exercise provision to exercise his vested options. The agreement also contains customary confidentiality, release, and non-disparagement provisions, and the Company agreed to pay accrued and unpaid salary, vacation time and attorney’s fees totaling approximately $45,000. Effective December 31, 2020, Dr. Wessel entered into a Separation and Severance Agreement with the Company. Pursuant to the terms of the agreement, the Company agreed to pay Dr. Wessel severance of $237,500 in accordance with his employment contract. In addition, Dr. Wessel’s options granted under the Company’s 2014 Stock Option and Equity Incentive Plan continued to vest until June 30, 2021. Dr.
Attorneys fees	$ 45,000
Dr.Wessel [Member]
Related Party Transactions (Details) [Line Items]
Description of agreement		Dr. Vitolo severance of $200,000 in accordance with his employment contract. In addition, Dr. Vitolo’s options granted under the Company’s 2014 Stock Option and Equity Incentive Plan continued to vest until September 6, 2020. Dr. Vitolo shall have until March 6, 2021 to exercise his vested options and he shall be allowed to use a cashless exercise provision to exercise his vested options. The agreement also contains customary confidentiality, release, and non-disparagement provisions, and the Company agreed to pay accrued and unpaid salary, vacation time and attorney’s fees totaling approximately $45,000. Effective December 31, 2020, Dr. Wessel entered into a Separation and Severance Agreement with the Company. Pursuant to the terms of the agreement, the Company agreed to pay Dr. Wessel severance of $237,500 in accordance with his employment contract. In addition, Dr. Wessel’s options granted under the Company’s 2014 Stock Option and Equity Incentive Plan continued to vest until June 30, 2021. Dr. Wessel shall have until December 31, 2021 to exercise his vested options and he shall be allowed to use a cashless exercise provision to exercise his vested options. The agreement also contains customary confidentiality, release, and non-disparagement provisions, and the Company agreed to pay accrued vacation time totaling approximately $28,940.
Accrued vacation fees		$ 28,940

Other Postretirement Benefit _2

Other Postretirement Benefit Plan (Details) - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2019
Retirement Benefits [Abstract]
Contribution expense	$ 10,261	$ 90,692	$ 20,081	$ 18,853
Employee contributions, description		The Company matches 100% of the first 3% of employee contributions, plus 50% of employee contributions that exceed 3% but do not exceed 5%.

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	Feb. 03, 2021	Jan. 07, 2021	Feb. 28, 2021	Mar. 15, 2021	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2019
Subsequent Events (Details) [Line Items]
Warrants shares					60,513	88,751	25,004
Vesting term, description	On February 3, 2021, the Company awarded a total of 25,000 options to a new employee with an exercise price of $34.47 and a 10-year term vesting over a four-year period.
Employee grant percentage		50.00%
Vesting term		4 years
Subsequent, description					The Company’s lease agreement at 880 Third Avenue expired on December 31, 2020 and has been renewed for calendar year 2021. Included in this lease is additional office space on the 10th floor along with the existing space on the 5th floor for an average monthly cost of approximately $8,730.
Monthly cost					$ 8,730
Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Warrants shares				271,366
Stock options exercised			141,625
Stock options exercise price			$ 3.30
Net proceeds			$ 467,772
Vesting term, description		Half of each award shall vest 6.25% per quarter starting 4/7/21. The other half of each award shall vest 25% on 1/7/22, then 6.25% per quarter, and shall be subject to the same forfeiture for contingencies as the management options.
Share based payment of award to option	25,000	1,490,000
Exercise price	$ 34.47
Vesting term	10 years
Milestones percentage		50.00%
Term of warrant		10 years
Warrant exercisable date		Jan. 7, 2021
Common Stock [Member] | Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Warrants issued				$ 5.31
Warrants exercise price				$ 1,441,382
Board of Directors [Member] | Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Vesting term, description		On January 7, 2021, the Company awarded a total of 1,490,000 options to employees and board of directors at an exercise price of $33.43 and a 10-year term vesting over a four-year period.
Exercise price		$ 33.43
Manfredi [Member] | Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Warrants shares		200,000
Warrants exercise price		$ 33.43
Pappagallo [Member] | Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Warrants shares		200,000
Warrants exercise price		$ 33.43